[1]胡安澜,周 荣,董凯旋,等.基于代谢重编程探讨肾小球硬化痰瘀互结病机[J].陕西中医,2025,46(1):88-91.[doi:DOI:10.3969/j.issn.1000-7369.2025.01.019]
　HU Anlan,ZHOU Rong,DONG Kaixuan,et al.A review of the Chinese medical theory of phlegm-stasis interactions in glomerulosclerotic diseases,with particular reference to metabolic reprogramming[J].,2025,46(1):88-91.[doi:DOI:10.3969/j.issn.1000-7369.2025.01.019]
点击复制

基于代谢重编程探讨肾小球硬化痰瘀互结病机
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年1期
页码:
88-91
栏目:
学术探讨
出版日期:
2025-01-05

文章信息/Info

Title:
A review of the Chinese medical theory of phlegm-stasis interactions in glomerulosclerotic diseases,with particular reference to metabolic reprogramming
作者:
胡安澜1; 周 荣1; 董凯旋1; 陈 曦1; 于小勇1; 李晓宁2
(1.陕西省中医医院,陕西 西安 710003; 2.西安医学院第三附属医院,陕西 西安 710068)
Author(s):
HU Anlan; ZHOU Rong; DONG Kaixuan; CHEN Xi; YU Xiaoyong; LI Xiaoning
(Shaanxi Provincial Hospital of Traditional Chinese Medicine,Xi'an 710003,China)
关键词:
代谢重编程;  线粒体;  能量代谢;  痰瘀理论;  肾小球硬化
Keywords:
Metabolic reprogramming;  Mitochondria;  Energy metabolism;  Phlegm and stasis theory;  Glomerular sclerosis
分类号:
R 629.6
DOI:
DOI:10.3969/j.issn.1000-7369.2025.01.019
文献标志码:
A
摘要:
肾小球硬化是肾小球病变的一种病理形态学特点,也是各种肾脏疾病进展的后期表现。临床常见为蛋白尿和肾病综合征,多数患者病情为逐渐进展。激素、免疫抑制剂治疗带来的不良反应和肝肾毒性,为肾小球硬化病变在中医药治疗上带来更多6空间。代谢重编程作为一种重要的细胞适应机制,在肾小球硬化病变的病理过程中扮演着核心角色。本文通过分析代谢重编程在肾小球硬化病变中的作用机制,探讨了痰瘀互结的病理机制,并从现代医学和传统中医相结合的角度提出了治疗肾小球硬化的潜在新策略,旨在为肾小球疾病防治提供新思路和方向。
Abstract:
Glomerular sclerosis(GS)is a prevalent consequence of glomerular injury and lesions resulting from a multitude of etiologies.It represents the primary pathological foundation for chronic renal failure.The disease is characterised by the proliferation of glomerular mesangial cells and the widening of the mesangial matrix.In the initial phase,the distribution is focal segmental,whereas in the subsequent phase,it becomes diffuse globular.Glomerulosclerosis is not referenced by name in the medical literature of previous generations.However,based on its clinical manifestations and characteristics,it can be attributed to the categories of zhenjiu and oedema in traditional Chinese medicine.The doctrine of phlegm and stasis is consistent with the development of GS,and TCM treatments guided by this doctrine have demonstrated efficacy in clinical settings.Metabolic reprogramming refers to the process by which cells adapt to different physiological or pathological states by regulating metabolic pathways and the production and utilisation of products.This regulation entails alterations in enzyme expression and activity,in addition to the synthesis,catabolism and transport of metabolites.The concept of metabolic reprogramming has been demonstrated in a variety of disease processes,including those affecting the liver and kidneys.This paper presents a discussion of the pathogenesis of glomerular sclerosis,with a particular focus on the role of metabolic reprogramming in the context of phlegm and stasis.The aim is to provide insights and directions for the treatment of glomerular diseases by combining Chinese and western medicine.

参考文献/References:

[1] 吕崇,贾清永.百令胶囊联合坎地沙坦治疗糖尿病肾小球硬化的效果观察[J].保健医学研究与实践,2022,19(7):9-12.
[2] 龙专,欧阳过,王敏,等.基于“气虚-能量代谢重塑”探讨马王堆导引术在慢性心力衰竭中的作用机制[J].湖南中医药大学学报,2020,40(1):1350-1354.
[3] 吕静,庞立健,吕晓东.运用肾络理论论治肾小球硬化[J].中华中医药学刊,2013,31(9):1928-1929.
[4] 郝贤.明清医家痰病证治钩玄[J].上海中医药杂志,2012,46(4):24-25.
[5] 陈佳永,庞延,潘朝锌,等.基于心肌能量代谢探讨中医药防治心力衰竭研究进展[J].陕西中医,2024,45(7):1002-1005.
[6] ZANELLA A,FERMO E,BIANCHI P,et al.Red cell pyruvate kinase deficiency:Molecular and clinical aspects.[J].Br J Haematol,2005,130(1):11-25.
[7] 尹春园.基于代谢组学的气虚血瘀证生物学基础研究[D].北京:北京中医药大学,2020.
[8] 李艳彦,梁琦.《血证论》水血相因思想初探[J].中医杂志,2015,56(9):731-733.
[9] 王永钧,张敏鸥.痰瘀互结与肾内微型癥积[J].中国中西医结合肾病杂志,2003,23(1):1-3.
[10] 黄勇,曹式丽.局灶节段性肾小球硬化之微观辨证[J].河南中医,2016,36(4):633-635.
[11] 肖党生,杨介钻,方辉.热能推动水液排泄是太阳经的生理基础[J].中国中医基础医学杂志,2020,26(1):25-29.
[12] WANG H,SHI J,SHI S,et al.Bibliometric analysis on the progress of chronic heart failure[J].Curr Probl Cardiol,2022,47(9):101213.
[13] 张依静,张彤,付艺.足细胞脂代谢重编程在肾小球疾病中的研究进展[J].东南大学学报(医学版),2024,43(2):293-299.
[14] JIANG W,HU J W,HE X R,et al.Statins:A repurposed drug to fight cancer[J].J Exp Clin Cancer Res,2021,40(1):241.
[15] 吕婕,朱永俊,林子艳,等.巨噬细胞代谢重编程在慢性肾脏病炎症损伤中的研究[J].临床肾脏病杂志,2024,24(5):417-421.
[16] MACHEDA M L,ROGERS S,BEST J D.Molecular and cellular regulation of glucose transporter(GLUT)proteins in cancer[J].J Cell Physiol,2005,202(3):654-662.
[17] HENDERSON N C,RIEDER F,WYNN T A.Fibrosis:From mechanisms to medicines[J].Nature,2020,587(7835):555-566.
[18] KANG H M,AHN S H,CHOI P,et al.Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development[J].Nat Med,2015,21(1):37-46.
[19] ZHAO X,PSARIANOS P,GHORAIE L S,et al.Metabolic regulation of dermal fibroblasts contributes to skin extracellular matrix homeostasis and fibrosis[J].Nat Metab,2019,1(1):147-157.
[20] MERAN S,STEADMAN R.Fibroblasts and myofibroblasts in renal fibrosis[J].Int J Exp Pathol,2011,92(3):158-167.
[21] 吴小燕,李丽艳,王莹琼,等.清化固肾排毒颗粒对单侧输尿管梗阻大鼠 COL4及FN影响[J].中华中医药学刊,2017,35(8):2115-2117.
[22] 韩斐.从痰瘀论治肾小球硬化的理论基础与临床研究[J].中国中医基础医学杂志,2013,19(9):1042-1043.
[23] 孙敬昌.从痰瘀论治肾小球硬化理论探析[J].中华中医药学刊,2007,25(8):1691-1693.
[24] 孟庆玉,李亚楠,牛丕丕,等.治疗慢性肾功能衰竭临床经验总结[J].中华中医药杂志,2018,33(7):2923-2925.
[25] 严晓华,金一顺,蓝健姿,等.脾肾通瘀饮联合ACEI对原发性局灶节段性肾小球硬化患者尿CTGF的影响[J].福建中医药大学学报,2013,23(6):6.
[26] SMALL D M,SANCHEZ W Y,GOBE G C.Intravital multi-photon imaging of the kidney:tubular structure and metabolism[J].Methods Mol Biol,2016,1397(12):155-172.
[27] 李蔓,陈亚楠,赵晰.中药复方延缓肾间质纤维化研究进展[J].云南中医中药杂志,2023,44(11):80-86.
[28] 陈威辛,戴恩来.基于“肾藏精”理论探讨局灶节段性肾小球硬化中足细胞与蛋白尿的关系[J].中医研究,2019,32(8):1-3.
[29] 郑贵珍,何改丽,高旭光,等.益气化瘀清热方通过调节SIRT1活性改善局灶节段性肾小球硬化肾病足细胞损伤[J].中药材,2021,44(9):2166-2172.
[30] 窦一田,李翀,马鸿杰,等.辛通畅络法复方肾苏Ⅱ阻抑局灶节段性肾小球硬化大鼠肾间质纤维化及转化生长因子β1表达的影响[J].天津医药,2017,45(3):239-244.
[31] 吴君,于晓斌,刘晓庆,等.五苓散干预小鼠肾间质纤维化Wnt/β-catenin信号通路的研究[J].中药新药与临床药理,2022,33(12):1639-1644.

相似文献/References:

[1]樊一波,文颖娟△,李 蒙,等.以脾胃为中心的葛根相关配伍对糖尿病心肌病大鼠受损心肌线粒体的改善作用*[J].陕西中医,2020,(10):1351.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.002]
　FAN Yibo,WEN Yingjuan,LI Meng,et al.Improving effect of Pueraria-related compatibility centered on spleen and stomach on injured myocardial mitochondria in DCM rats[J].,2020,(1):1351.[doi:DOI:10.3969/j.issn.1000-7369.2020.10.002]
[2]吴 鹏,邢俊娥,曹凌群,等.藿苓益智方对阿尔茨海默病模型小鼠神经细胞凋亡线粒体通路的作用研究[J].陕西中医,2021,(4):411.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.001]
　WU Peng,XING Jun'e,CAO Lingqun,et al.Study on the effect of Huoling Yizhi recipe on miton of mitochondria pathway of neuron apoptosis in Alzheimer's disease model mice[J].,2021,(1):411.[doi:DOI:10.3969/j.issn.1000-7369.2020.04.001]
[3]董秀娟,曹若愚,于洪基,等.大蒜素对子宫内膜异位症大鼠异位病灶及缺氧诱导因子-1α表达的影响[J].陕西中医,2022,(4):432.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.005]
　DONG Xiujuan,CAO Ruoyu,YU Hongji,et al.Effects of Allicin on the ectopic lesions and the expression of HIF-1α in rats with endometriosis[J].,2022,(1):432.[doi:DOI:10.3969/j.issn.1000-7369.2022.04.005]
[4]陈佳永,庞 延,潘朝锌,等.基于心肌能量代谢探讨中医药防治心力衰竭研究进展[J].陕西中医,2024,(7):1002.[doi:DOI:10.3969/j.issn.1000-7369.2024.07.032]
　CHEN Jiayong,PANG Yan,PAN Chaoxin,et al.Research progress of traditional Chinese medicine in prevention and treatment of heart failure based on myocardial energy metabolism[J].,2024,(1):1002.[doi:DOI:10.3969/j.issn.1000-7369.2024.07.032]
[5]蒋沈华,虞坚尔,冯其茂.中药保护线粒体功能在慢性心力衰竭治疗中的应用进展[J].陕西中医,2024,(7):1006.[doi:DOI:10.3969/j.issn.1000-7369.2024.07.033]
[6]陈 西,罗 岚,宁东红,等.胶艾汤对模拟特发性流产的线粒体调控作用机制[J].陕西中医,2025,46(1):31.[doi:DOI:10.3969/j.issn.1000-7369.2025.01.006]
　CHEN Xi,LUO Lan,NING Donghong,et al.The mechanism of mitochondrial regulation by Jiao Ai decoction in a model of idiopathic miscarriage[J].,2025,46(1):31.[doi:DOI:10.3969/j.issn.1000-7369.2025.01.006]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(82174366); 陕西省科技厅社发攻关一般项目(2017SF-298); 陕西省中医药管理局科研项目(2021-GJ-LC022); 西安市科技计划项目[2019115613YX011SF044(9)]
更新日期/Last Update: 2025-01-09